Illumina and Genpathway Announce Partnership to Provide Whole-Genome ChIP-Sequencing Services
News May 01, 2008
Illumina, Inc. and Genpathway have announced the formation of a partnership to provide researchers whole-genome chromatin immunoprecipitation (ChIP) sequencing services. Samples are first prepared using Genpathway’s FactorPath ChIP assays, and then sequenced by the Genome Analyzer through Illumina’s Sequencing Services.
Final data analysis is completed by Genpathway using their proprietary software analysis tools. Combined, the Illumina and Genpathway services provide researchers with access to a complete ChIP-sequencing solution for identifying and quantifying transcription factor binding sites across the entire genome.
Specifically, the combined services include cell or tissue processing, antibody selection and qualification, ChIP using Genpathway’s optimized procedures for greater sensitivity and specificity, ChIP DNA amplification, quality-control steps throughout the assay, Sequencing Services using Illumina’s Genome Analyzer, and complete data analysis by Genpathway. Additional information about Illumina’s Sequencing Services with Genpathway’s ChIP assays and data-analysis services can be accessed at www.illumina.com/ChIPsequencingservices.
“We are delighted to team up with Illumina, a world leader in sequencing, to offer the most powerful and comprehensive ChIP-sequencing services available,” said Mary Harper, Ph.D., Chief Scientific Officer of Genpathway. “One of the top applications for sequencing is ChIP, a notoriously time-consuming and difficult procedure. Combining Genpathway’s expertise in ChIP and data-analysis services with Illumina’s high-throughput next-generation sequencing technology and services provides researchers a faster path to discovery.”
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE